We, along with Nasdaq, want to acknowledge the incredible leadership and contributions from our Chief Financial Officer, Melissa Tosca. The recent move to CFO follows the many successes in the capital markets, strategic planning, and building out the invaluable finance team at Kiora.
Kiora Pharmaceuticals, Inc.
Biotechnologie
Improving sight in patients with severe vision loss
Info
Kiora Pharmaceuticals, Inc. (Kiora) is a clinical development-stage company focusing on novel therapeutics for the treatment of orphan retinal diseases with high unmet need. Publicly traded on the NASDAQ under KPRX, our mission is to help patients improve their ocular health and restore vision.
- Website
-
https://kiorapharma.com/
Externer Link zu Kiora Pharmaceuticals, Inc.
- Branche
- Biotechnologie
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Encinitas, California
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 2013
- Spezialgebiete
- Ophthalmology, Drug Development, Vision Restoration und Opthalmic Therapies
Orte
-
Primär
332 Encinitas Blvd
Suite 102
Encinitas, California 92024, US
-
Reisnerstraße 34/1
Vienna, 1030, AT
-
697 Burke Road
Suite 201
Camberwell, VIC 3124, AU
Updates
-
$KPRX ICYMI, view the fireside chat from the Canaccord Genuity Growth Conference between Brian Strem, Ph.D., and John Newman, Ph.D., CFA discussing KIO-301, KIO-104 and upcoming milestones for Kiora. https://lnkd.in/gGHFgBAc
-
-
Today we reported our 2nd quarter results showing the progress we've made across all business fronts this year. Notably, we finalized design of a Phase 2 study of KIO-301 in retinitis pigmentosa in partnership with Thea; advanced KIO-104 toward a Phase 2 trial in inflammatory retinal disease; and ended the quarter with $27.8 mm and an expected cash runway into 2027. We invite you to read More > https://lnkd.in/eSBnfNbH
-
Inspiring collaboration embracing diversity and creating a sense of belonging for children with low vision and blindness.
In partnership with the American Foundation for the Blind (AFB), Barbie proudly introduces the first Blind Barbie Fashionista doll, developed to authentically represent blind and low-vision individuals. This doll features an upward and outward eye gaze, sunglasses, and a cane with a marshmallow tip. Textured fabrics enhance the sensory experience, making fashion elements more accessible with easy-to-open Braille packaging, and elbow articulation for comfortable cane use, facilitating accessibility to show that we are all Barbie: https://lnkd.in/eu-SXBBV. Exlpore More About the Blind Fashionista Barbie on the Mattel, Inc. Website: https://lnkd.in/eksmAA3c.
-
-
Chief Development Officer,, Eric Daniels, M.D., to present at the Jones Trading Healthcare Seaside Summit Mon., July 15 at 6:15 pm ET. Investors can access the latest update on our pipeline of drugs targeting retinal disease either live or by replay at the following link https://lnkd.in/eJHgpCrF
Jones Healthcare Seaside Summit 2024
ir.kiorapharma.com
-
We are honored to welcome Lisa Walters-Hoffert to the Board of Directors at Kiora Pharmaceuticals. With decades of experience in biotech, Lisa will bring expertise in strategic development, governance, finance, and capital markets. Join us in welcoming Lisa on our journey to bring about new treatments for retinal diseases. https://lnkd.in/eNQQK3E7
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors
ir.kiorapharma.com
-
Kiora welcomes Roger Goldberg, M.D., to its SAB. We look forward to the scientific insights and clinical perspectives he can bring to our development of new therapeutics for retinal diseases. https://lnkd.in/gESzb34X
-
-
We recently had the opportunity to present alongside like-minded innovators developing new treatment options for retinal disease. Listen below to our talk on our innovations for inherited and inflammatory retinal conditions. Thank you Ophthalmology Innovation Source https://lnkd.in/efvG23Uf
Kiora Pharmaceuticals | Brian Strem, CEO
https://www.youtube.com/
-
We would like to share additional MRI data from our ABACUS-1 study of KIO-301 reported from the ARVO medical conference this weekend. The presented data showed a statistically significant increase in brain activity in the visual cortex, as assessed by functional MRI, in patients with retinitis pigmentosa. Importantly, this increase was found to be time-dependent and demonstrated concordance with previously reported improvements in visual field, visual acuity, and functional vision. We invite you to review the full announcement and presentation here - https://lnkd.in/eB-8-BzE
-
-
There's a wonderful network of caregivers, doctors, nurses, families, and advocacy groups supporting greater independence to people who are blind or visually impaired. Today, we also want to recognize the incredible life of Trigger, a furry friend who fathered more than 300 guide dogs before retiring. https://lnkd.in/ewtpWQjF
Guide dog dubbed Dogfather retires after fathering 300 puppies
bbc.com
Ähnliche Seiten
Finanzierung
Letzte Runde
Kapitalerhöhung nach Börsengang15.000.000,00 $